Administration of resveratrol to treat inflammatory respiratory disorders

• US 6,878,751 B1
• Filed: 10/19/2000
• Issued: 04/12/2005
• Est. Priority Date: 10/19/2000
• Status: Expired due to Fees

• Current Assignee: Imperial College Innovations Ltd. (Imperial College London), Imperial College of Science Technology & Medicine (Imperial College London)
• Original Assignee: Imperial College Innovations Ltd. (Imperial College London), Imperial College of Science Technology & Medicine (Imperial College London)
• Inventors: Barnes, Peter John, Donnelly, Louise Elizabeth
• Primary Examiner(s): Henley, III, Raymond
• Assistant Examiner(s): DELACROIX MUIRHEI, CYBILLE
• Application Number:
  US09/694,108
• Time in Patent Office: 1,636 Days
• Field of Search: 514/733, 514/734, 514/736
• US Class Current: 514/733
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/7034 attached to a carbocyclic compound, e.g. phloridzin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics

Abstract

A method is provided for treating inflammatory respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The method involves administration, preferably oral or pulmonary administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.

Claims

1. A method for treating interstitial lung disease in a patient suffering from or predisposed to developing interstitial lung disease (ILD), comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations thereof.

2. The method of claim 1, wherein the active agent is cis-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

3. The method of claim 2, wherein the active agent is cis-resveratrol.

4. The method of claim 2, wherein the active agent is a conjugate of cis-resveratrol and a mono- or di-saccharide.

5. The method of claim 4, wherein the active agent is cis-resveratrol glucoside.

6. The method of claim 1, wherein the active agent is trans-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

7. The method of claim 6, wherein the active agent is trans-resveratrol.

8. The method of claim 6, wherein the active agent is a conjugate of trans-resveratrol and a mono- or di-saccharide.

9. The method of claim 8, wherein the active agent is trans-resveratrol glucoside.

10. The method of claim 1, wherein the active agent comprises a mixture of cis-resveratrol and trans-resveratrol.

11. The method of claim 1, wherein the active agent is delivered orally.

12. The method of claim 1, wherein the active agent is delivered by pulmonary administration.

13. The method of claim 1, wherein the active agent is delivered parenterally.

14. The method of claim 13, wherein the active agent is delivered to the alveoli.

15. The method of claim 1, further comprising the co-administration of an additional active agent.

16. The method of claim 15, wherein the formulation further includes an additional active agent.

17. The method of claim 16, wherein the additional active agent is selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

18. The method of claim 17, wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting β

₂ adrenergic agonists, and combinations thereof.

19. The method of claim 18, wherein the additional active agent is selected from the group consisting of theophylline, salmetrol xinafoate, and a combination thereof.

20. The method of claim 1, wherein the ILD is fibrosing alveolitis, sarcoidiosis, or fibrotic lung disease.